Form 8-K - Current report:
SEC Accession No. 0001140361-24-042352
Filing Date
2024-09-30
Accepted
2024-09-30 16:31:03
Documents
14
Period of Report
2024-09-30
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20036442_8k.htm   iXBRL 8-K 60712
2 EXHIBIT 10.1 ef20036442_ex10-1.htm EX-10.1 169784
  Complete submission text file 0001140361-24-042352.txt   410776

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA acst-20240930.xsd EX-101.SCH 3859
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE acst-20240930_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acst-20240930_pre.xml EX-101.PRE 16040
16 EXTRACTED XBRL INSTANCE DOCUMENT ef20036442_8k_htm.xml XML 4222
Mailing Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540
Business Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540 609-649-9272
Acasti Pharma Inc. (Filer) CIK: 0001444192 (see all company filings)

EIN.: 000000000 | State of Incorp.: A8 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-35776 | Film No.: 241339879
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)